This article is more than 5 years old. Information may no longer be current.

Alembic’s generic dorzolamide hydrochloride solution approved

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alembic Pharmaceuticals’ abbreviated new drug application for dorzolamide hydrochloride ophthalmic solution USP 2% has been approved by the FDA, according to a press release.

Indicated for the treatment of elevated IOP in ocular hypertension or open-angle glaucoma patients, it is therapeutically equivalent to Trusopt ophthalmic solution 2% (Merck), the release said.

The market size for dorzolamide is estimated to be $35 million, the release said.